American Heart Association awards $2.1m to research link between migraine, strokes and CVD
Betsy Goodfellow | July 27, 2023 | News story | Research and Development | American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the link between migraines, strokes and cardiovascular disease (CVD).
Prior research has shown that some types of migraine can increase the risk of strokes, as well as there being evidence to suggest that they can lead to other types of CVD. Therefore, the American Heart Association is providing $2.1m in grants for seven research projects from Brigham and Women’s Hospital in Massachusetts; Mayo Clinic in Minnesota; Mayo Clinic in Arizona; Duke University School of Medicine in North Carolina; Rhode Island Hospital in Providence; the University of South Carolina in Columbia; and Yeshiva University in New York City, all US.
The projects began on 1 July 2023, and are funded for up to two years.
Mitchell S V Elkind, MD MS FAHA, chief clinical science officer of the American Heart Association, commented: “According to the American Migraine Foundation, 39 million people in the US experience migraines. And while evidence suggests that migraines increase the risk of strokes and possibly other types of CVDs, there is still much we don’t know about what causes this increased risk. With these new research grants, we hope to create a collaborative group of experts in migraine, cardiovascular disease, stroke, biostatistics and data science to explore these unanswered questions about the cardiovascular complications of migraine.”
Betsy Goodfellow
Related Content
Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
